FarmaKology-Gene Therapy Could Treat Pitt-Hopkins Syndrome

May 12, 2022

Today's Company

MOMA Therapeutics

MOMA Therapeutics are on a mission to unlock molecular machines by understanding and respecting their complexities. We’ll be working incredibly hard to discover their untapped potential because we believe they are the key to delivering the next generation of precision medicines. We are unapologetically scientific, and we know this will help us achieve our mission to get new medicines to people in need. We’ve removed the bureaucracy and believe having a teammate’s back is critical to our success. You see, MOMA isn’t your typical biotech company. We are drug discovery professionals, industry specialists and scientific experts. More importantly, we’re collectively unstoppable.

News

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19

Eli Lilly and Company and Incyte announced today the U.S. Food and Drug Administration has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4-mg once daily for 14 days or until hospital discharge, whichever comes first.

Strategikon Pharma Announces the Release of Clinical Maestro® SOURCE 3.0

Strategikon Pharma announced today the release of Clinical Maestro® SOURCE version 3.0. An innovative solution that addresses the clinical RFP outsourcing process, SOURCE replaces outdated Excel-based workbooks with a powerful SaaS solution, designed by the world’s leading experts in clinical outsourcing, our biopharmaceutical customers.

Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs , today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), enabling the Company to initiate its planned Phase 1 clinical study of RGLS8529 in healthy volunteers.

PrecisionLife and Sano Genetics announce partnership to accelerate understanding of long COVID and help identify new treatments

PrecisionLife Limited, a global techbio company using its deep insights into disease biology and patient stratification to drive precision medicine in chronic diseases, is pleased to announce a partnership with Sano Genetics, a genetic research platform enabling patients to participate in ethical research projects, to advance understanding of the long-term effects of coronavirus infection (long COVID).